MedPage Today on MSN

Non-ablative treatment for BPH/LUTS achieves rapid, sustained improvements

Results with Optilume consistent in clinical trials and real world, regardless of prostate ...

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross(R) Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.